


Journal of Materials Chemistry B

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Strontium modified calcium phosphate cements – approaches towards targeted stimulation of bone turnover

Matthias Schumacher^{1*}, Michael Gelinsky¹

¹ Centre for Translational Bone, Joint and Soft Tissue Research, Medical Faculty and University Hospital, Technische Universität Dresden, Dresden, Germany

*Corresponding author: matthias.schumacher@tu-dresden.de

Keywords: Calcium phosphate, bone cement, strontium, hydroxyapatite, brushite

Abstract

Making use of the potential of calcium phosphates to host a variety of ions in their crystal lattice, ion substitution of calcium phosphate bone cements became subject of intense investigations in the last years, since this approach allows to stabilize a bone defect and to locally deliver therapeutic ions into a specific defect site at the same time. In this respect significant attention has been given to strontium ions (Sr^{2+}) lately. Strontium possesses the unique potential to both stimulate new bone formation and inhibit cell-driven bone resorption and thus have been used successfully in systemic osteoporosis therapy. Strontium doping of calcium phosphate bone cements might allow making use of this dual effect to promote local bone defect healing. The goal of this review is to provide an overview of different routes that have been employed to obtain strontium-containing calcium phosphate bone cements and describe their material characteristics as well as their biological properties based on cell culture and animal studies.

1 Introduction

Biomaterials, in terms of materials intended to come into contact with living tissue or to be implanted into a living organism are usually described on the basis of their specific degree of biocompatibility. Although various definitions of “biocompatibility” exist, most of them are based on absence of negative tissue reaction and/or formation of a fibrous interface.¹ For example, materials in contact to bone tissue are required to allow the formation of a strong bone-material interface in order to support the mechanical integrity of the host bone. Biomaterials for hard tissue repair have been in focus of research for many years now. Calcium phosphates (CaP), in particular hydroxyapatite (HA) and brushite (DCPA), are widely used in bone graft applications as well as in coatings of metallic implants, since their chemical resemblance to the mineral part of the natural bone offers excellent biocompatibility.^{1,2} Since some mixtures of calcium phosphates can, once in contact with water, undergo a hydraulic setting reaction into either HA or DCPA, a number of self-setting cements has been developed of which many are in clinical use today. Calcium phosphate bone cements (CPC) in general can be shaped into a specific bone defect during implantation, are highly biocompatible and are bio-resorbable.³ However, only recently concepts beyond “simple” biocompatibility have been developed: on the one hand tissue engineering aims on the implantation of cell seeded, functional biomaterial scaffolds; on the other hand materials with an intrinsic potential to influence the host tissue have been proposed. Such “third generation biomaterials” are meant to (locally) evoke a specific cellular response based on the cell-material interaction.⁴ These may be materials that contain and locally release drugs upon implantation as well as materials which are composed of biologically effective components that are released as soon as the implants degrade in the body. Much effort has been made to investigate the potential of CaP and CPC comprising biologically potent ions, such as silicate,⁵⁻⁸ magnesium⁹⁻¹¹ and many others.^{2,12} Whilst drug delivery from CaP bone cements has been reviewed in detail recently,¹³ this study is focussed on cements comprising biologically highly effective strontium ions (Sr^{2+}). Strontium has been proposed to possess both a bone formation stimulating and at the same time anti-resorptive effect and is thus used in systemic osteoporosis therapy.¹⁴

Our aim is to provide a rationale for the development of Sr-laden CaP bone cements for the treatment of bone defects, an overview of different routes that have been employed to obtain such cements as well as their material characteristics, *in vitro* and *in vivo* properties.

1.1 Strontium in bone

Strontium (Sr) is an alkaline earth metal accounting for approx. 0.02-0.03% of the earth's crust.^{15,16} Its concentration in drinking water varies with geographic region, but is generally low, for example less than 1 mg/ml in the United States.¹⁶ A typical diet contains about 2-4 mg Sr/day,^{15,16} and the secretion of Sr exceeds that of Ca, accounting for a fairly low bioavailability of orally ingested Sr of ~20%.¹⁷ Since Sr²⁺ is generally regarded as bone-seeking and thus could remain in the body for a long time once ingested, the interest in strontium metabolism arose from radioactive ⁹⁰Sr atmospheric contamination following the nuclear weapons tests since 1945.¹⁵ Radioactive isotopes of Sr have also been used for diagnostic purposes.¹⁵ Strontium was discovered to follow the metabolic pathways and signalling principles known for calcium, although the response to Sr²⁺ tends to be weaker. Strontium shows a comparable protein binding capacity as Ca and is mostly deposited in the bone mineral.¹⁵ In 1952 Shorr and Carter described an increased calcium absorption and thus bone formation under the influence of strontium lactate (SrC₆H₁₂O₆ · x H₂O).¹⁸ A first clinical trial, where patients with postmenopausal osteoporosis received up to 1.75 g/d Sr in form of strontium lactate over a period between 3 months and 3 years showed an increase in bone mass under Sr administration and a potential benefit in osteoporosis therapy without any side effects.^{19,20} Systematic studies revealed the bone conserving effect of divalent strontium in ovariectomized (OVX) rats,²¹ until two clinical phase III trials showed a significant increase in bone mass under the influence of 2 g/d S-12911 (strontium ranelate, SrRan) in post-menopausal women.^{22,23}

Unlike most other drugs used in osteoporosis therapy, Sr exerts a dual effect on bone remodelling, being able to enhance osteoblast activity and thus increase new bone formation and at the same time inhibit osteoclast activity and thus reduce cellular bone resorption (Figure 1).²⁴⁻²⁷ Several *in vitro* studies confirmed this twofold effect of Sr on bone metabolism. For example, osteoblast precursor proliferation and expression of extracellular matrix proteins are increased by ~10⁻³ mM Sr²⁺, and

osteoblast-mediated bone formation is stimulated in the presence of 2-5 $\mu\text{g/ml}$ ($2.3\text{-}5.7\cdot 10^{-3}$ mM) Sr^{2+} .^{28,29} Although the exact mechanism of how Sr affects bone cells remains unknown, it has been proposed that Sr acts on the *calcium sensing receptor* (CaSR) expressed by bone cells as a calcium-like entity and thus interacts with signalling pathways associated with the Ca-driven regulation of bone metabolism.^{30,31} Furthermore, an increase of β -catenin expression indicating an enhanced transcription of osteogenic factors, a decrease in Wnt-pathway inhibitors as well as an enhanced prostaglandin-expression under the influence of Sr have been described.^{30,32} Interestingly, similar concentrations of Sr inhibit the formation of osteoclasts and their resorption activity through either paracrine signalling³³⁻³⁵ or even the induction of osteoclast apoptosis.³⁶




Fig. 1 Effects of Sr^{2+} ions on bone metabolism: Stimulation of osteoblast-precursor proliferation and osteogenic differentiation (1), increase of bone mineralisation by osteoblasts (2), reduced osteoclast-precursor recruitment and osteoclastogenesis (3), decreased resorption activity and increased apoptosis of mature osteoclasts (4) as well as interaction with the osteoblast/osteoclast paracrine signalling (5).

1.2 Calcium phosphate bone cements

First described by LeGeros as well as Brown and Chow in the 1980ies, calcium phosphate cements (CPC) have become a frequently used biomaterial in clinical application today.³⁷⁻³⁹ CPC are hydraulic cements and are usually prepared by mixing one or more calcium orthophosphate powders (the so called precursor) with an

aqueous liquid. A list of CaP phases frequently used to prepare CPC is given in Table 1.

Tab. 1 Calcium phosphate species frequently used to prepare CPC.^{3,40}

Name	Abbreviation	Chemical formula	Ca/P ratio	pH*
Calcium dihydrogen phosphate monohydrate	MCPM	$\text{Ca}(\text{H}_2\text{PO}_4)_2 \cdot \text{H}_2\text{O}$	0.5	0–2.0
Calcium dihydrogen phosphate (anhydrous)	MCPA	$\text{Ca}(\text{H}_2\text{PO}_4)_2$	0.5	-
Calcium hydrogen phosphate dihydrate (brushite)	DCPD	$\text{CaHPO}_4 \cdot 2 \text{H}_2\text{O}$	1.0	2.0–6.0
Calcium hydrogen phosphate anhydrous (monetite)	DCPA	CaHPO_4	1.0	-
Octacalcium phosphate	OCP	$\text{Ca}_8(\text{HPO}_4)_2(\text{PO}_4)_4 \cdot 5 \text{H}_2\text{O}$	1.33	5.5–7.0
α -Tricalcium phosphate	α -TCP	$\alpha\text{-Ca}_3(\text{PO}_4)_2$	1.5	-
β -Tricalcium phosphate	β -TCP	$\beta\text{-Ca}_3(\text{PO}_4)_2$	1.5	-
Amorphous calcium phosphate	ACP	$\text{Ca}_x\text{H}_y(\text{PO}_4)_z \cdot n \text{H}_2\text{O}$ $n = 3\text{-}4.5$	-	>5
Ca-deficient Hydroxyapatite	CDHA	$\text{Ca}_{10-x}(\text{HPO}_4)_x(\text{PO}_4)_{6-x}(\text{OH})_{2-x}$ ($0 < x < 1$)	-	6.5–9.5
Hydroxyapatite	HA	$\text{Ca}_5(\text{PO}_4)_3\text{OH}$	1.67	>9.5
Tetracalcium phosphate	TTCP	$\text{Ca}_4(\text{PO}_4)_2\text{O}$	2.0	-


*stability range in aqueous media at 25°C

Upon mixing of the precursor with the liquid phase a paste forms that will self-set and harden via a hydraulic reaction, characterised by dissolution of the precursor components and the precipitation of a thermodynamically more stable setting product. Mechanical integrity results from the entanglement of the newly formed crystals.⁴¹ Although a large number of CPC formulations have been proposed all of them set into one of two possible end products at 37°C: hydroxyapatite ($\text{Ca}_5(\text{PO}_4)_3(\text{OH})$, HA), as the most stable phase at pH values >4.2, or brushite ($\text{CaHPO}_4 \cdot 2 \text{H}_2\text{O}$, DCPD), which is the result of the setting reaction at pH<4.2.³ The chemical nature of the reaction can, in principle, be either an acid-base reaction (e.g. the brushite-forming reaction of the acidic MCPM with slightly basic β -TCP) or the


conversion of a metastable phase, as amorphous calcium phosphate (ACP) or α -TCP, into a more stable one.^{3,40} The setting reaction will lead to the hardening of the paste within a characteristic time span (setting time).

Apatite-forming cements

Since the mineral part of natural bone is composed of Ca-deficient hydroxyapatite containing a variety of substitutions such as carbonate, magnesium, sodium etc. (referred to as “bone apatite”)¹, the choice of HA-forming cements for bone repair is self-evident. The classical apatite-forming cement of Brown and Chow is based on the reaction of basic tetracalcium phosphate with calcium hydrogen phosphate (equation 1):³⁸



Numerous other cement formulations have been proposed based on the setting reaction of one more acidic and one more basic CaP component, e.g. combinations of α -TCP with MCPM and CaO or the reaction of TTCP, β -TCP and MCPM.^{42,43} Driessens and co-workers developed a cement setting into carbonated, Ca-deficient HA more similar to the natural bone apatite (equation 2).⁴⁴




One second category is cements derived from a one-component precursor that set via the conversion of a less stable CaP phase into hydroxyapatite upon mixture with water, e.g. the hydrolysis of α -TCP and its re-precipitation into CDHA or the conversion of ACP into HA.^{45,46} Apatite-forming cements possess a very low solubility according to their setting product: CDHA has a slightly higher solubility than stoichiometric HA (table 2). This leads to relatively low physico-chemical degradation.⁴⁷ However, apatite cements can be resorbed *in vivo* via cellular activity (osteoclastic resorption),⁴⁸ although the degree of resorption seems to depend on the actual setting product (HA or CDHA), the respective degree of crystallinity and the porosity. Mechanical characterisation revealed compressive strength values of completely set HA-forming cements is up to 70-80 MPa.^{40,41}

Tab. 2 Solubility of various CPC and SrCPC components and setting products.

Components with low solubility			
Formula	Solubility at 25°C [-log(K_{sp})]	Solubility at 25°C [mg/l]	Reference
α-TCP	25.5	2.5	49,50
β-TCP	28.9	0.5	49,50
CaHPO ₄ (DCPA)	6.90	48	49,50
SrHPO ₄ (DSPA)	6.7-6.9	63	51
CaCO ₃	4.90	14	52,53
SrCO ₃	8.10	10	52,53
CDHA	~85.1	~9.4	3,49
HA	58.4-116.8	0.3	3,49,50
DCPD/brushite	6.59	88	49,50
SrHA (0.3-10% Sr ²⁺)	115-117	-	54,55
Sr-brushite	increased (comp. to brushite)	-	56
TTCP	38-44	0.7	49,50
Highly soluble components			
Formula	Solubility at 25°C [g/l]	Reference	
SrCl ₂	1060	52,53	
Sr(NO ₃) ₂	800	52	

Brushite-forming cements

Invented by Mirtchi and Lemaître in 1987, brushite is the second possible end product of hydraulic CPC reactions.⁵⁷ The most common formulation is based on an equimolar mixture of β-TCP and MCPM as given in equation 3.⁵⁸



Other formulations comprise β-TCP and phosphoric acid or MCPM, tetracalcium phosphate and CaO, but are all based on an acid-base reaction mechanism.^{59,60} In general, brushite cements possess a much higher solubility (Table 2) and thus a higher degradation rate than HA under physiological conditions.⁶¹ Moreover, because of its metastable nature, at pH>6 brushite hydrolyses into CDHA over time, which may lead to the release of orthophosphoric acid that could cause the inflammatory

tissue response sometimes reported after implantation of large quantities of brushite-forming cements.⁶² Brushite can also be resorbed by cellular activity *in vitro* and *in vivo*.^{61,63} However, setting of brushite cements takes place at low pH values and such acidification may not only complicate the cellular reaction *in vitro* but also hamper tissue integration *in vivo*. Brushite cements are mechanically slightly weaker than apatite forming cements. Compressive strength values of up to 60 MPa have been reported.⁴⁰

2 Strontium-modified CaP cements

The potential of CPC to host various ions like Na⁺, K⁺, Mg²⁺, Sr²⁺, CO₃²⁻, Cl⁻ etc. has been described early.⁴¹ Given the ability of some ions (calcium, phosphate, strontium, silicate, zinc and magnesium) to trigger bone cell response and their advantages over bioactive proteins like growth factors, such as lower cost and better stability, the local release of therapeutically potent ions from an implanted bone cement could have big impact on bone healing strategies.¹³ In 2000, Li *et al.* published the development of a SrHA (strontium-substituted HA) containing resin-based bone cements with good mechanical and *in vitro* characteristics.⁶⁴ Recently, the synthesis and characterisation of Sr-containing CPC (SrCPC) has become focus of many studies. From a crystallographic point of view, the basis of all those developments is that strontium, as some other divalent cations, can be integrated into the crystal lattice of calcium phosphates on Ca²⁺ positions over a wide range of concentrations preserving the respective crystal structure.^{56,65,66} It was reported that Sr²⁺ can substitute Ca²⁺ in a number of CaP phases, including amorphous calcium phosphate, hydroxyapatite, octacalcium phosphate and brushite.⁶⁷ In hydroxyapatite, Sr²⁺ can occupy either the Ca(I) or Ca(II) position, although Ca(I) is only preferred at very low levels of substitution.⁶⁸ Due to its bigger ionic radius (Ca²⁺: 148 pm; Sr²⁺: 158 pm in hexagonal hydroxyapatite)⁶⁹ strontium substitution causes a linear increase in apatite lattice parameters.^{54,68,70} In higher concentrations Sr substitution has been shown to decrease the crystallinity.^{68,71} In case of brushite, substitution of Ca²⁺ by Sr²⁺ ions is not limited to specific Ca sites and causes an expansion of the unit cell volume and thus a shift in the X-ray diffraction peaks towards lower diffraction angles.⁶⁷ The same effect can be found in α - and β -TCP.⁷²⁻⁷⁴ β -TCP was shown to possess the ability to host up to 80 at-% strontium which is accompanied by a linear increase of the lattice

parameters.⁷² Lattice distortion induced by the larger Sr^{2+} ions has been found to be in charge of the increased solubility of substituted apatite and brushite.^{55,56} However, even fully substituted apatite (Ca free strontium-apatite) possesses a solubility higher than that of pure HA (Figure 2) despite of being as highly ordered as HA.⁵⁵ Thus substitution could help to enhance *in vivo* degradability and, consequently, osseointegration of SrCPC. Moreover, Sr can affect the conversion of α -TCP to CDHA and could therefore be used as a tool to modulate setting characteristics.⁷⁵ In particular, Sr^{2+} (and other divalent cations as Mg^{2+} , Ba^{2+} , Zn^{2+} and Cu^{2+})⁷⁶⁻⁷⁸ has been shown to block α -TCP hydrolysis. In the context of CPC this could decelerate conversion into CDHA and thus setting, a principle that was recently employed to prevent aqueous α -TCP pastes from setting and thus to obtain storable cement precursor pastes that can be activated upon mixture with a second, Ca^{2+} containing liquid.⁷⁸ The presence of Sr^{2+} has further been shown to affect the rate of apatite nucleation;⁷⁹ in particular, under the influence of Sr^{2+} apatite deposition on HA samples from a Ca^{2+} and Sr^{2+} containing solution, but, interestingly, this effect was less pronounced if the substrate was SrHA.⁵⁴




Fig. 2 Solubility isotherms of hydroxyapatite (“HAp”) and “Sr-HAp” with different degrees of Sr-substitution. Reprinted from Acta Biomaterialia 5, 5, H. B. Pan et al., Solubility of strontium-substituted apatite by solid titration, 1678-1685, 2009, with permission from Elsevier.

In principle there are four possible ways to obtain strontium containing or strontium substituted calcium phosphate cements: one can (a) add Sr-containing phases to an existing cement system, (b) substitute calcium phases in the cement precursor

powder by their strontium analogues (e.g. substitution of CaHPO_4 by SrHPO_4), (c) use Sr-substituted reactive CaP phases as component in the precursor (e.g. Sr-substituted α -TCP) or (d) use a strontium-salt-containing solution as liquid phase during cement paste preparation (Figure 3).




Fig. 3 Processing routes towards SrCPC: addition of Sr-containing reagents (a), substitution of reagents by their Sr-equivalents (b), use of Sr-substituted reagents in the precursor (c) and use of a Sr-containing liquid (d).

As for CPC, setting of SrCPC depends on the solubility of the precursor powder components.⁸⁰ During setting, the Sr component can either act as inert filler or undergo dissolution and re-precipitation as the other precursor components or crystallise from the liquid. Besides the respective solubility of the precursor phases the overall $(\text{Ca}+\text{Sr})/\text{P}$ ratio of the powder has to be taken into account, since both an excess or shortage of cations (Ca^{2+} , Sr^{2+}) can inhibit the setting reaction, alter the setting product or decrease the reaction yield. Regarding the end-product of the setting reaction, cement matrices with embedded Sr-rich clusters (those systems where the Sr component does not undergo complete dissolution) can be distinguished from monophasic apatite matrices with Sr^{2+} substituted into the crystal lattice. Another mechanism has been proposed by Kuang *et al.* who attributes the initial hardening of the cement to a fast chelate reaction of Ca/Sr ions and carboxy groups from carboxylic acids (such as citric acid) in the cement liquid.^{81,82}

Table 3 summarises different approaches towards preparation of SrCPC and indicates the either mono- or biphasic nature of the set cement.

Tab. 3 Selected Sr-containing cement formulations and setting products (m: monophasic cement matrix, b: biphasic cement matrix).

Sr-source	Solid or liquid	Precursor phases	Setting products	Mono or biphasic	Ref.
DSPA	s	TTCP, DCPA, DSPA	SrHA	m	83,84
SrCO ₃	s	CaCO ₃ , SrCO ₃ , DCPD	HA, SrCO ₃	b	85
SrCO ₃	s	α -TCP, HA, DCPA, CaCO ₃ /SrCO ₃	HA, SrCO ₃	b	86
SrCO ₃	s	ACP, DCPD, SrCO ₃	HA, SrCO ₃	b	87
SrCO ₃	s	DCPD, CaO/SrCO ₃	SrHA	b	88
ASP	s	ACP, ASP, DCPD	SrHA, HA	b	89
SrACP	s	SrACP, DCPA	SrHA, SrCO ₃ after ageing SrHA	b	90
Sr- α -TCP	s	Sr- α -TCP	SrHA	m	73
SrCO ₃ + SrHPO ₄	s	α -TCP, DSPA, SrCO ₃ , HA	not characterized	-	91
DSPA	s	TTCP, DCPA/DSPA*	SrHA	m	81
SrHA W**	s	B-TCP, DCPA, Sr-HA-whiskers	not characterized	b	92
SrCl ₂	l	α -TCP/Gelatin, DCPD	SrCDHA	m	75
SrCl ₂	l	CaCO ₃ , DCPD	SrHA	m	85
SrCl ₂	l	α -TCP	SrHA	m	93
Sr(NO ₃) ₂	l	α -TCP, TTCP	SrHA	m	94

ACP: amorphous calcium phosphate, **ASP**: amorphous strontium phosphate, **DCPA**: monetite, **DCPD**: brushite, **DSPA**: strontium hydrogen phosphate anhydrous, **SrACP**: strontium-substituted ACP, **Sr- α -TCP**: strontium-substituted α -TCP, **SrCDHA**: Sr containing Ca-deficient HA, **TTCP**: tetra-calcium phosphate,

* Liquid component did contain polymeric additives.

** Whiskers.

2.1 Apatite-forming formulations

Certainly the most straight-forward way to introduce Sr into a cement is the addition of a Sr-containing phase to the cement powder. Wang *et al.* intermixed SrCO₃ with an ACP/DCPD cement precursor by intense milling and found a retarded setting of the cement into HA. The set cement was characterised by a smaller grain size, which can be attributed to the milling process. However, SrCO₃ was still detected in the XRD spectra of the set cements and thus Sr did not quantitatively substitute into the apatite lattice.⁸⁷ Another cement was obtained by addition of SrCO₃ particles with a size of ~10 μm to a cement containing α-TCP, DCPA, HA and CaCO₃. Here, no additional milling step was used, and therefore the set cement was characterised by relatively large SrCO₃ clusters embedded in an apatite matrix.⁸⁶ Furthermore, with the aim of mechanical reinforcement of the cement, SrHA whiskers prepared using a hydrothermal synthesis route were added to a β-TCP/DCPD cement precursor by Shen and co-workers.⁹²

Another approach to obtain Sr-containing HA cements is the substitution of Ca-phases by their Sr analogues. For example, using the cementing reaction of DCPA/TTCP into hydroxyapatite upon mixture with phosphoric acid, DCPA can be substituted by its strontium analogue strontium hydrogen phosphate (SrHPO₄, DSPA). In this way, Sr-substituted apatite cements with a Sr/(Sr+Ca) ratio of up to 0.1 were prepared by Guo *et al.*^{83,84}

Since mixtures of DCPD and CaCO₃ can set into HA, one strategy to obtain SrHA cements is to replace CaCO₃ in the precursor by SrCO₃. Following this approach, precursors composed of DCPD and various CaCO₃/SrCO₃ mixtures were prepared by Tadier *et al.* to obtain cements with up to 8 wt-% Sr.⁸⁵ In contrast to the above-mentioned systems, the setting product was biphasic: the set cement was composed of a mixture of hydroxyapatite and SrCO₃ and no SrHA could be detected. Similarly, no homogenous Sr-distribution was achieved by a precursor mixture of DCPD and amorphous calcium phosphate (ACP) in which the latter was partially replaced by amorphous strontium phosphate (ASP). Although total Sr/(Sr+Ca) ratios between 0.025 and 0.1 could be obtained the set cement was composed of coexistent HA and SrHA.⁸⁹ On the other hand, in an α-TCP/DCPA/HA/CaCO₃ cement system setting into CDHA substitution of CaCO₃ by SrCO₃ in the precursor powder mixture was shown to result in the formation of a monophasic, Sr-substituted apatite matrix and

enhanced mechanical properties after setting..⁸⁶ Baier *et al.* replaced both DCPA and CaCO_3 by DSPA and SrCO_3 in an α -TCP cement and obtained good *in vivo* results, however, no material characterisation of that cement was published.⁹¹ SrCO_3 was also successfully used to gradually replace CaO in a DCPD/CaO cement, resulting in the formation of a SrHA matrix via several intermediate steps.⁸⁸ However, the Sr/(Ca+Sr) ratio that can be achieved by substituting a Ca phase by its Sr analogue is limited to the fraction the respective Ca phase contributes to the total precursor. Therefore, and despite of the elaborate synthesis mostly required to obtain Sr-substituted CaP phases which are often not commercially available, such phases can easily be used to introduce varying amounts of Sr into CPC. For example, the cement forming reaction based on the hydrolysis of α -TCP into HA upon mixture with aqueous Na_2HPO_4 results in SrHA when α -TCP is substituted by Sr- α -TCP although a reduced reactivity was found for Sr- α -TCP synthesised at high temperatures.⁷³ In a more complex system based on ACP and DCPD, Sr-substituted ACP (SrACP) prepared by gradual replacement of $\text{Ca}(\text{NO}_3)_2$ by $\text{Sr}(\text{NO}_3)_2$ during ACP precipitation from an aqueous solution allows the preparation of cements setting into SrHA.⁸⁹ Similarly, SrACP prepared from DCPA, calcium hydroxide and SrCO_3 via a dry mechanochemical approach was employed as Sr source to obtain cements with Sr/(Sr+Ca) ratios between 0.025 and 0.2. Although SrCO_3 residues were detected in the set cement at early time points, ongoing hydration lead to a decrease in SrCO_3 content and substitution of Sr^{2+} -ions in the apatite matrix.⁹⁰

Based on a cement liquid containing various concentrations of SrCl_2 , cements setting into monophasic Sr-containing apatite can be prepared from α -TCP⁹³ and α -TCP/Gelatin⁷⁵ as well as DCPA/ CaCO_3 precursor powders.⁸⁵ Due to the solubility of SrCl_2 and the limited liquid to powder ratio (l/p) a maximum of 6 wt-% strontium content could be achieved by the second method. During immersion in water, this cement was shown to release around 80% of the contained strontium within 21 days, indicating a higher solubility of the poorly crystalline, Sr-substituted apatite cement matrix formed during setting.⁸⁵ Similarly, when strontium nitrate was mixed into the liquid phase of an α -TCP/TTCP cement the resulting SrHA with up to 4.3 wt-% Sr released more Sr than Ca.⁹⁴

2.2 Brushite-forming cements

Most brushite forming cement formulations comprising strontium are based on the synthesis of Sr-substituted precursor phases. One approach is to synthesise Sr-substituted TCP as reactive species. Alkhraisat *et al.*⁷⁴ obtained Sr- β -TCP by sintering CaHPO₄ with mixtures of CaCO₃ and SrCO₃, thus obtaining Sr- β -TCP with molar Sr/(Sr+Ca) ratios between 0 and 0.33. These were used in a hydraulically setting cement upon equimolar mixture with MCPM. Lattice parameters of the setting product brushite indicated a substitution of Ca²⁺ by Sr²⁺ ions in the set cement. After a small initial burst, a constant release of Sr-ions from the cements was found during immersion in water, releasing up to 2.3 mg strontium per g cement strontium within 15 days. However, no impact of the Sr-modification on the mechanical properties was found. Another Sr-substituted CPC setting to brushite based on α -TCP was described by Pina *et al.*^{95,96} Firstly, Sr- β -TCP was synthesised via aqueous precipitation from calcium nitrate, diammonium hydrogen phosphate and strontium with a (Ca+Sr)/P molar ratio of 1.5, allowing the precipitation of TCP. The precipitate was subsequently treated thermally at 1500°C to obtain Sr- α -TCP. To accelerate setting, an aqueous solution of citric acid was used as cement liquid, and poly(ethylene glycol) or hydroxyl propyl methylcellulose were added to enhance washout resistance of the cement paste. The cement set into brushite with Sr²⁺ ions substituted into the crystal structure. In contrast to the cement described by Alkhraisat *et al.*, this cement exhibited an increased compressive strength compared to a reference material prepared from Sr-free α -TCP.

Based on the addition of Sr via the liquid phase, another cement that sets into Sr-brushite is based on the reaction of β -TCP and MCP in the presence of up to 10 wt-% SrCl₂ and traces of sodium pyrophosphate.⁵⁶ In this system high Sr content lead to a slight decrease in diametral tensile strength of the set cements.

Tab. 4 Selected Sr-containing cement formulations setting into brushite.

Sr-source	Solid/liquid	Precursor phases	Setting products	Ref.
Sr- β -TCP	S	Sr- β -TCP, MCP	Sr-brushite	74
Sr- α -TCP	S	Sr- α -TCP*	Sr-brushite	95,96
SrCl ₂	S	β -TCP, MCP, SPP, SrCl ₂	Sr-brushite	56

MCPM: calcium dihydrogen phosphate (monohydrate), **SPP**: sodium pyrophosphate, **Sr- α -TCP**: strontium-substituted α -TCP, **Sr- β -TCP**: Sr-substituted β -TCP.

* cement also contained poly ethylene glycol (PEG) or hydroxyl propyl methylcellulose (HPMC).

3 Properties of SrCPC

3.1 Cement setting and injectability

Setting of CPC has been demonstrated to be fundamentally altered by the presence of Sr²⁺ ions by Guo *et al.* when SrHPO₄ was added to a TTCP/DCPA system. Hydration was retarded significantly, which was attributed to the higher degree of supersaturation that is required to yield Sr-containing apatite crystals. Furthermore, the transformation rate into HA or SrHA, respectively, was reduced in the presence of Sr albeit this could be partially compensated by higher phosphoric acid content in the cement liquid.⁸⁴ Cements comprising Sr phases as reactants to form SrHA tend to have prolonged setting times if SrCO₃ or DSPA is used as Sr source.^{81,83,86} Sr substitution in ACP, on the contrary, induced faster setting in SrACP/DCPA systems.⁹⁰ Setting time of ACP/DCPD cements was reported to significantly increase with addition of SrCO₃ (with at the same time decreasing viscosity of the cement paste).⁸⁷ Hydrolysis α -TCP into CDHA was shown to be decreased in the presence of Sr-containing solution.⁹⁷ The addition of SrCO₃ into α -TCP based cements merely affected setting time, which could be due to the fact that SrCO₃ did not participate in the setting reaction.⁸⁶ Sr substituted TCP, whether in form of α -TCP setting to SrHA⁷³ or α - or β -TCP in brushite forming cements⁷⁴ was shown to slow down the cement setting, although Pina *et al.* stated that lattice distortion caused by Sr substitution enhanced TCP reactivity and did not hinder the conversion of brushite into apatite.⁹⁵

In most cases, the retarding effect of Sr on the nucleation and crystal growth of apatite results in the formation of much smaller crystals during cement

setting.^{81,86,87,90} This is illustrated in Figure 4, where smaller crystals are visible after setting of an Sr-containing, ACP/DCPD-based cement comprising SrCO₃ as Sr source are visible. However, some studies either reported no visible differences in the microstructure of the set cements⁸³ or at least partially attributed differences in the crystal size to variations in milling parameters during precursor preparation.⁸⁶




Fig. 4 SEM micrographs of set samples of Sr-free (A) and Sr-containing (B) CPC derived from an ACP/DCPD and ACP/SrCO₃/DCPD precursor, respectively. Reprinted from *Acta Biomaterialia* 3, 5, X. Wang et al., Influence of a novel radiopacifier on the properties of an injectable calcium phosphate cement, 757-763, 2007, with permission from Elsevier.

Since bone defect treatment via minimally invasive surgical techniques (e.g. in spinal surgery or in order to reinforce osteoporotic bones) gained considerable attention over the last years, controlled injectability of both apatite and brushite cements is of interest.^{98,99} Besides powder-to-liquid-ratio, particle size distribution (controlled by precursor milling time) and organic additives like poly(ethylene glycol) or methylcellulose, ion substitution also affects cement setting and thus injectability.⁹⁶ By enhancing the reactivity of α -TCP strontium shortens the setting time and thus impairs the injectability of brushite-forming cements based on Sr- α -TCP.⁹⁶ On the contrary, SrCO₃-laden apatite cements were found to gain injectability with increasing Sr-content due to a decrease in viscosity of the cement paste.⁸⁷ However, since injectability is also a function of precursor particle size (and size distribution) no general conclusions can be drawn when comparing different studies.

3.2 Degradation and Strontium-ion release

Degradation of CPC describes the physico-chemical dissolution of the set cements in aqueous environments and is usually quantified by the release of Ca^{2+} and phosphate ions. Obviously, this process is controlled by the solubility of the cement components (Table 2), but also by parameters like porosity, surface roughness and area as well as material fragmentation. In general, brushite degrades much faster than hydroxyapatite. Depending on the experimental setup, precipitation of CaP crystals from Ca and phosphate containing immersion liquids can even lead to a virtually negative degradation rate, making it difficult to compare the effects of Sr modification on degradation in different studies. It is, however, general consensus that lattice expansion induced by the larger Sr^{2+} ions upon integration in the apatite lattice increases solubility, and consequently higher degradation was demonstrated for SrHA and SrHA forming cements.^{54,55,93,100}

There are two mechanisms that can contribute to the release of Sr^{2+} from a SrCPC. One is the diffusion of Sr^{2+} from soluble phases in the cement matrix via micro pores in the cement caused by the cement liquid, and the second is the physico-chemical dissolution of cement matrix itself. During immersion in large volumes of Ca^{2+} and Sr^{2+} free buffer solution (*sink* conditions), Sr modification by the addition of solid SrCO_3 lead to a reduced Ca^{2+} release in a system that set into a SrCO_3 -containing, bisphasic HA matrix.⁸⁵ Interestingly, Sr introduction into the same cement system via the liquid phase, resulting in a monophasic SrHA matrix, had the opposite effect on Ca^{2+} release and the Ca^{2+} release increased compared to the Sr-free control cement. Sr^{2+} , on the other hand, was released to a greater extent from the biphasic cement containing SrCO_3 clusters, where ~80% of the initially contained Sr were released within 21 days immersion in water.⁸⁵ The latter effect was also found in an α -TCP-based cement system, where cumulative Sr^{2+} release from a set biphasic HA/ SrCO_3 bulk cement did only account for 1.5% of the initially added Sr but exceeded the release from a monophasic SrHA over 21 days in salt buffer solution.^{85,86} It can be hypothesized that this difference was due to the Sr^{2+} release via dissolution of SrCO_3

crystals on the one hand and the either diffusion-controlled or degradation-associated Sr release on the other. In a diffusion-controlled system, a depletion of Sr at the sample surface should occur, and leaching of Sr^{2+} from the sample surface was shown for monophasic SrHA cements.^{85,86} In SrCO_3/HA cements, a decrease of Sr-concentration at the surface of samples immersed in liquid for 35 days was also present and was traceable even further into the bulk cement, suggesting that diffusion can be a limiting factor also in biphasic cements.⁸⁶ Using monophasic SrHA cements prepared using a $\text{Sr}(\text{NO}_3)_2$ solution, Leroux *et al.* proposed a two-stage degradation mechanism, comprising an initial phase where Sr^{2+} exceeds Ca^{2+} release due to the dissolution of strontium nitrate traces in the set cement, followed by the congruent release of Sr^{2+} and Ca^{2+} according to the ratio contained in the cement during bulk dissolution. Still, only 2 and 4 wt-% of the contained Ca and Sr, respectively, were released within one month.⁹⁴

Although ion release and degradation can more easily be studied in ion-free buffer solutions, more complex immersion media are required to obtain results comparable to the *in vitro* (or *in vivo*) situation. Typical for α -TCP-based materials is a slight acidification and a depletion of Ca^{2+} concentration in the immersion medium that arises from the presence of CDHA and the progressive formation of apatite crystals.^{101,102} Since material-mediated Ca depletion can have significant impact on the cellular response^{103,104} it is important to note that Sr modification can, in some systems, alter this effect. For an α -TCP/DCPA/ CaCO_3 /HA-based apatite cement immersed in alpha minimum essential cell culture medium (α MEM) Ca^{2+} concentration was shown to drop from 1.8 mM to ~ 0.5 mM and remain low over 21 days despite of a regular medium change. Strontium modification, either by addition of SrCO_3 crystals or substitution of CaCO_3 by SrCO_3 in the precursor, resulted in a significant reduction of Ca depletion. Sr was, at the same time, released in higher doses from monophasic SrHA forming cements, resulting in concentrations of 0.05-0.1 mM compared to 0.025-0.05 mM for SrCO_3/HA biphasic cements.¹⁰⁵

For brushite-forming cements prepared from Sr substituted β -TCP a high, zero-order release of Sr was found during immersion in water. Up to 2.3 mg/g Sr were released, and kinetics of Sr release resembled the one measured for Ca, indicating that Sr was released by bulk erosion.⁷⁴ In an approach where Sr was introduced into the cement via the liquid phase an increase in solubility with increasing Sr-content was described.⁵⁶

It is obvious that degradation and thus Sr^{2+} release differs from any laboratory setup as soon as a SrCPC is implanted into a tissue defect. Besides the complexity of body fluid compared to any of the buffer solutions described above, diffusion processes within the tissue as well as (cell-driven) active ion transport occur. Still several *in vivo* studies demonstrated an increased degradation of SrCPC compared to the respective Sr-free control groups and thus confirmed the above findings.^{106,107} However, Sr^{2+} release did in no case result in an increase of serum strontium levels to concentrations comparable to strontium ranelate treatment, suggesting that released Sr^{2+} is accumulated in the surrounding bone.⁹¹

3.3 Mechanical characteristics of SrCPC

As all inorganic cements and ceramics, CPC in general exhibit brittle fracture behaviour. Compared to natural bone (*cancellous bone*: 5-15 MPa and 0.26-0.90 GPa, *cortical bone*: 133-193 MPa and 17-25 GPa compressive strength and compression modulus, respectively)^{1,108} most CPC possess poor mechanical strength and thus are mainly intended to be used in non-load-bearing situations. Brushite cements tend to have lower compressive strength (10-60 MPa)¹⁰⁹⁻¹¹¹ than hydroxyapatite forming ones (up to 75 MPa),^{109,112} depending mainly on phase composition of the set cement as well as on the respective porosity.¹¹²

In SrCPC, contradicting results have been found regarding mechanical characteristics that are summarized in Table 5. It is important to note that the different preparation routes and properties of the set samples, such as porosity, do not allow direct comparison of the mechanical characteristics. In general, strength of the cements increases within the first days to weeks as hydration proceeds. In most

cements setting into monophasic SrHA strontium modification either increased compressive strength^{83,86,90} or had no significant effect on the mechanical characteristics.⁸¹ Nevertheless, one study reported a decrease in compressive strength of Sr- α -TCP cements compared to Sr-free control.⁷³ This was attributed to a decreased reactivity of the precursor that derived from the high sintering temperature during Sr- α -TCP synthesis that caused a larger crystal size and therefore slower dissolution speed that was also obvious from the prolonged setting time. To explain the higher strength of most SrHA cements based on multi-component precursors, Yu *et al.* suggest an increase in Ca 2p and P 2p binding strength in the Sr-substituted apatite lattice as measured by XPS.⁹⁰ Other parameters in discussion are the occurrence of crystal defects and the inhibiting effect of Sr on the apatite depositing rate.⁸³ In their TTCP/DCPA/DSPA cement system, Guo *et al.* described a non-linear influence of Sr content on the mechanical properties: while an optimum composition was found at a Sr/(Sr+Ca) ratio of 0.05 with an increase of compressive strength up to 66 MPa compared to ~50 MPa for the Sr-free reference cement, higher Sr content resulted in a reduced compressive strength.^{83,84} A comparable optimum was described for DCPD-based cements where SrCO₃ replaced the second precursor component, CaO.⁸⁸ Here, up to 1.5% molar fraction of SrCO₃ increased compressive strength of the set cement from ~7 to ~20 MPa. Again, higher substitution resulted in decreased strength values. In contrast Kuang *et al.* found no effect on the mechanical properties for the same cement system with partial or complete substitution of DCPA by DSPA (Sr/(Sr+Ca) = 0-0.2), although overall compressive strength was significantly lower (~12 MPa after 28 days).⁸¹ Still, in this cement a polymer component had been added to the cement liquid that might have interfered with the setting process. Full replacement of DCPA by DSPA and CaCO₃ by SrCO₃, on the other hand, reduced the compressive strength of α -TCP/DCPA/CaCO₃/HA cements.⁹¹ In contrast, in another monophasic system, up to 8.37 wt-% strontium in SrHA derived from a α -TCP/DCPA/HA/CaCO₃ precursor by substitution of CaCO₃ by SrCO₃, increased compressive strength significantly from 32 to 53 MPa.⁸⁶ In a SrACP/DCPD cement higher compressive strength values were found for Sr/(Sr+Ca)

ratios between 0.025 and 0.2 (up to 75 MPa after 10 days) compared to Sr-free reference cement. Although residues of SrCO₃ were present in the cement at early time points, hydration was shown to lead to a decrease in SrCO₃ content and the integration of Sr in the apatite matrix.⁹⁰ Sr modification via the cement liquid also results in the formation of SrHA, however, only modest impact on the mechanical properties was described by Panzavolta *et al.*, where 1 wt-% substitution increased compressive strength, whilst higher substitution resulted in decreased strength.⁷⁵

In cement systems setting into HA/SrCO₃ composite matrices, a decrease of mechanical strength compared to unmodified cement control samples was reported. This was explained by the low binding strength of SrCO₃ residues and the surrounding apatite matrix and the role of these crystals as crack initiators under compression loading.⁸⁶ Wang *et al.* postulated a small amount of Sr substitution into the HA lattice from intermixed SrCO₃ particles and thus a small increase in compressive strength, whilst at higher SrCO₃ loading ratios compressive strength also decreased.⁸⁷ In contrast to residual SrCO₃ clusters with poorly defined morphology, addition of SrHA whiskers was shown to significantly increase the strength of set cements at concentrations of 2.5 and 5 wt-%. This result was attributed to the entanglement of the elongated whiskers, although at higher contents (10 wt-%) a decrease of compressive strength was found.⁹²

In brushite forming cements based on Sr-β-TCP the presence of Sr did merely affect the compressive strength, as well as porosity, although a tendency to set into monetite instead of brushite was found at Sr contents up to 20 at-%.⁷⁴ In contrast, Pina *et al.* found elevated compressive strength in Sr-α-TCP based cements, and attributed this to the reduced conversion of the precursor in the mechanically weaker setting product brushite. However, the high solubility of brushite leads to a fast degradation of the cement that resulted in a decrease of strength over time.⁹⁵

In general, the either mono- or biphasic nature of the setting product of the respective cement system seems to be a key parameter for the mechanical properties: while the gain in strength caused by crystal lattice deformation associated with Sr substitution

can lead to a certain increase in both apatite and brushite cement strength the presence of secondary clusters impairs the mechanical integrity of the set cement (Figure 5).




Fig. 5 Comparison of compressive strength values of natural bone, different SrCPC (**m**: mono- and **b**: biphasic setting product) and their respective Sr-free reference materials. (**x**) indicate the highest strength values of other HA and brushite cements described in the literature.^{1,73-75,81,83,85-88,90,95,108}

Tab. 5 Properties of set SrCPC.

Setting product	Porosity [vol-%]	Compressive strength [MPa]*	Initial setting time [min]	Final setting time [min]	Ref.
SrHA (m)	n/a	~ 66 (+)	(+)	(+)	83
SrHA (m)	52 (-)	n/a	n/a	n/a	85
SrHA (m)	<5	12-13 (/)	6-34 (-)	13-82 (-)	81
SrHA (m)	n/a	~10 (-)	(-)	(-)	73
SrHA (m)	56-58	63-74 (+)	21-28 (+)	37-52 (+)	90
SrHA (m)	30-42 (+)	~53 (+)	~13 min (+)	~ 33 min (+)	86
SrHA (m)	n/a	10-20 (+)	11-17 (+)	17-21 (+)	88
SrCDHA (m)	38-47 (+)	4-13 (+/-)	4-20 (+)	9-50 (+)	75
HA/SrCO ₃ (b)	(+)	40 (+)	~30-40 (+)	~45-55 (+)	87
HA/SrCO ₃ (b)	49 (-)	n/a	n/a	n/a	85
HA/SrCO ₃ (b)	26-40 (-)	~15 (-)	~7 min (/)	~26 min (/)	86
Sr-brushite (m)	~50 (/)	~5-6 (/)	2-5 (+)	n/a	74
Sr-brushite (m)	n/a	~22 (+)	3-7 (+)	n/a	95

(+) increased, (/) unaffected, (-) decreased (against Sr free reference). m = monophasic, b = biphasic cement matrix after setting.

* for series with different Sr/(Sr+Ca) ratios the maximum strength is shown.

3.4 Radiopacity

Apart from the therapeutic benefits of Sr modification and possible improvement of mechanical properties, another rationale to introduce Sr-phases into CaP bone cements is their increasing effect on the adsorption of X-rays. This is of interest since high radiopacity is required to monitor the positioning of injectable cements during surgery and follow-up imaging. Various species such as SrCl_2 , SrCO_3 , SrBr_2 , SrF_2 have been evaluated to modify CPC^{86-88,90,113,114} or calcium-aluminium-phosphate cements¹¹⁵ for that purpose. In most cases an increase of radiopacity with Sr content was shown. For example, Wang *et al.* demonstrated that 4-20% Sr substitution allow to distinguish SrCPC from bone samples with the same thickness in radiographic images (Figure 6).⁸⁷ When comparing cements setting to SrHA and SrCO_3/HA the latter showed less increase of radiopacity at similar Sr contents which was attributed to the low resolution of the radiographic imaging that could not correctly represent small local contrast variations as to be expected in biphasic matrices.⁸⁶




Fig. 6 Radiograph of cortical bone and CPC samples (5 mm thickness) with 4-20% Sr content. Reprinted from *Acta Biomaterialia* 3, 5, X. Wang *et al.*, Influence of a novel radiopacifier on the properties of an injectable calcium phosphate cement, 757-763, 2007, with permission from Elsevier.

3.5 Biological properties based on cell culture studies

Only few data has been published on the *in vitro* characteristics of Sr-modified CPC. In general, Sr modification does not induce cytotoxicity. In cell cultures treated with extracts of SrHA,^{81,86} biphasic HA/SrCO_3 ⁸⁶ and SrHA-whisker reinforced cements,⁹² a positive effect of the Sr doping and/or the Sr^{2+} released from the cements was found on cell proliferation and osteogenic differentiation. It was further stated that the decreased tendency of SrCPC to cause medium Ca^{2+} depletion as well as a smaller variation in the pH during SrCPC setting may contribute to these findings.⁸⁶ Only one

study described a slight cytotoxic effect of high concentrated SrHA extracts on the murine connective tissue cell line L929.⁸³ Table 6 shows an overview of the *in vitro* effects of SrCPC. For example, Tadier *et al.* found a higher proliferation rate of osteoprogenitor cells on biphasic SrCO₃/HA compared to monophasic SrHA cements that were derived from a DCPD/CaCO₃/SrCO₃ precursor. However, on mRNA level there was no difference in osteogenic differentiation.⁸⁵ In contrast two different routes of Sr modification based on an α -TCP precursor, setting into SrHA and SrCO₃/HA, respectively, were both shown to stimulate proliferation and osteogenic differentiation of primary human mesenchymal stem cells.¹⁰⁵ Interestingly, proliferation was generally more enhanced in samples kept under basal cell culture conditions, whilst cells cultured in medium supplemented with osteogenic additives showed higher proliferation on monophasic SrHA cement matrices. This indicates different susceptibilities of cells towards Sr depending on their stage of differentiation. No cytotoxicity (using MG63 osteoblast-like cells in an indirect culture setup) as well as an enhanced proliferation and osteogenic differentiation in a direct setup using MC3T3-E1 murine pre-osteoblasts were also found for TTCP/DCPA/DSPA based SrHA cements. A comparable cell morphology was found on SrCPC and Sr free controls.¹⁰⁷ Similarly, enhanced proliferation and osteogenic differentiation were observed for MG63 osteoblasts cultured on α -TCP/Gelatine/DCPD cements where Sr was introduced via the liquid phase.⁷⁵ Since the stimulatory effect of Sr modification was found in indirect cell culture setups as well as in direct contact cultures, it can be hypothesised that different aspects contribute to the positive cell reaction: release of Sr²⁺ from the cement, altered ionic interaction of cement and the cell culture medium, resulting in e.g. reduced Ca²⁺ depletion and reduced acidification of the medium.^{85,105}

In Sr containing brushite cements prepared from Sr- β -TCP and MCPM, no distinct influence of Sr content on proliferation and metabolic activity of human osteoblasts was found in a direct setup. The cement released up to 40 ppm (0.56 mM) strontium.⁷⁴ However, this release test was performed during immersion in water, and might not correctly represent the situation in cell culture conditions, as it is known that

e.g. protein content of immersion solutions can limit ion release.¹¹⁶ In comparison to Zn-doped brushite cements additional doping with Sr was shown to increase metabolic activity of murine osteoblast precursors.¹¹⁷ Therefore it can be concluded that the beneficial effects of Sr on both proliferation and differentiation of osteogenic cells was confirmed for SrCPC.

Until today, to our best knowledge no data has been published on the osteoclastic resorption of Sr containing CPC *in vitro*. Still, the anti-resorptive effect of Sr incorporated in hydroxyapatite has been demonstrated by Yang *et al.* using mineralised films prepared by precipitation from Ca and Sr containing liquids, that somewhat resemble the characteristics of set CPCs: osteoclastic activity, by means of resorption pit area, was significantly decreased in the presence of different Sr²⁺ concentrations while osteoblast proliferation increased in a Sr dose-dependent manner and osteoblast activity remained unaffected.¹¹⁸

Tab. 6 Properties of selected SrCPC in cell culture experiment.

Setting product(s)	Sr content	Cell type	Sr ²⁺ concentration in cell culture medium	Cell proliferation	Osteogenic differentiation	Cell culture setup: extract (E), direct (D) or powdered cement (P)	Ref.
SrCDHA (m)	0-5 wt-%	MG63	n/a	increased with Sr content	increased*	D	75
SrHA (m)	0-6 wt-%	hBMSC	< 10 ppm	no effect	no effect*	D	85
HA/SrCO ₃ (b)	0-8 wt-%	hBMSC	< 200 ppm	increased with Sr	no effect*	D	85
SrHA (m)	0-10% Sr/(Sr+Ca)	L929	n/a	no effect	n/a	E	83
SrHA (m)	0-8.37 wt-%	hBMSC	0.025-0.125 mM	increased*	increased*	E,D	105
HA/SrCO ₃ (b)	0-5.4 wt-%	hBMSC	0.05-0.14 mM	increased*	increased*	E,D	105
SrHA (m)	0-33% Sr/(Sr+Ca)	MG63 MC3T3 E1	n/a	increased*	increased*	E,D	81,107
HA/SrHA-whisker (b)		MG63	0.171-1.39 mM	increased	n/a	E	92
Sr-brushite (m)	0-33% Sr/(Sr+Ca)	hFOB1.19	n/a (10-40 mg/ml measured in water)	unaffected*	n/a	D	74
ZnSr-brushite	2.1 mol-%	MC3T3-E1	n/a	increased	unaffected*	E, P	117

MG62: human osteoblast-like cell line; **hBMSC**: human bone marrow-derived stromal/stem cells; **L929**: murine connective tissue cell line; **hFOB1.19**: human fetal osteoblast cell line; **MC3T3-E1**: murine pre-osteoblast cell line.

* against Sr free reference

3.6 *In vivo* studies on strontium-containing cements

Although the stimulating effect of systemically administered strontium ranelate on bone formation has been questioned recently,¹¹⁹ evidence exists that the local release of Sr^{2+} into a specific bone defect can support defect healing. One of the first studies using a Sr-containing bone cement *in vivo* was published by Ni *et al.* in 2006, although SrHA was only used as a filler in a resin-based cement.¹²⁰ However, promising results were obtained, with the Sr-laden cement exhibiting an increased bonding strength to bone compared to the Sr-free PMMA cement control group. Positive results for new bone formation at the bone-implant area of SrHA-containing polymeric cements were also described by others.¹²¹⁻¹²⁴ Wong *et al.* pointed out that neither inflammatory response nor necrotic reactions or fibrous encapsulation that occurred in the PMMA control group were found in the SrHA-PMMA cement group.¹²³

In vivo studies focussing on SrCPC of different compositions are summarised in Table 7. In an intramuscular implantation study, Dagang Guo *et al.* demonstrated an increase of material degradation with increasing Sr/(Ca+Sr) ratio using pre-set cylinders prepared from a TTCP/DCPA/DSPA cement with up to 10% strontium substitution.¹⁰⁶ This was confirmed in bone contact when the same material was implanted into a femoral drill hole defect. Furthermore, a tight bond of newly formed bone was found at the interface between the cement and the host bone. Similarly, Kuang *et al.* implanted pre-set TTCP/DCPA/DSPA based SrHA cement cylinders in a metaphyseal drill-hole defect model in rats.¹⁰⁷ Again, enhanced degradation was found for SrHA compared to Sr-free reference after 32 weeks; however, it remains unclear whether this was caused by higher physico-chemical dissolution or cellular resorption. Early endochondral ossification after 2 weeks and higher new bone deposition (4 weeks post operation) indicated an enhanced osteo-regenerative potential of the SrHA cement, although only a small number of animals was used. In another study, it was shown that a SrHA cement accelerated graft healing in anterior cruciate ligament reconstruction using allogenic ligament grafts impregnated with a Sr-containing cement in comparison to Sr-free control.¹²⁵

To study the effects of Sr-modified CaP intended to positively influence the bone metabolism in osteoporotic bone *in vivo*, the key issue is to select an appropriate animal model that resembles the human osteoporotic fracture situation.¹²⁶ Baier *et al.* implanted an α -TCP/SDPA/SrCO₃/HA cement in a metaphyseal drill hole defect in ovariectomized rats in comparison to a Sr free reference cement.⁹¹ It is interesting to note that the occurrence of discontinuities within the cement appeared as a key for cement integration into the bone tissue, since new bone formation was found at these sites and was even enhanced in case of Sr-laden cement. Moreover, BMD measurements revealed a local increase of bone in the cement-treated metaphyseal region, suggesting that Sr released from the cements lead to a local bone-anabolic effect. This is supported by a recent study, where ToF-SIMS imaging was used to visualize Sr-distribution in histological sections of the metaphyseal region of rat femora where a SrHA cement based on α -TCP, DCPA, SrCO₃ and HA had been implanted to bridge a wedge-shaped critical size defect resembling a typical osteoporotic fracture (Figure 7).¹²⁷ Furthermore, histomorphometric analysis of bone formation as well as immunohistochemical analysis of bone-related markers confirmed an increased bone formation and remodelling activity in the Sr-HA group.




Fig. 7 Histological overview of the implant region where a Sr-modified CPC was implanted into a metaphyseal critical-size defect in femora of ovariectomized rats (A) and mass distribution of Ca⁺ (B), Sr⁺ (C) and C₄H₈N⁺ (D) and overlay of Ca⁺, Sr⁺ and C₄H₈N⁺ (E) as measured by ToF-SIMS. Reprinted from *Biomaterials*, 34, U. Thormann *et al.*, Bone formation induced by strontium modified calcium phosphate cement in critical-size metaphyseal fracture defects in ovariectomized rats, 8589-8598, 2013, with permission from Elsevier.

Only one study focussing on the *in vivo* properties of Sr-containing brushite cement has been published so far: In a trabecular bone defect in pigs Pina *et al.* demonstrated positive effects of Sr co-doping of a Zn-containing brushite cement. Sr doping was found to reduce the osteoclast density at the bone-implant interface and to increase new bone formation.¹¹⁷

Although data on the *in vivo* effects of SrCPC are sparse, published data strongly suggests that the concept of Sr doping of CPC positively influence local bone regeneration. In particular animal studies in osteoporotic models revealed promising results towards the utilisation of SrCPC in the clinical treatment of osteoporosis related fractures.

Tab. 7 Summary of animal studies on SrCPC.

Cement type	Animal model	Type of defect	Results	ref.
SrHA (pre-set)	8-10 month old New Zealand rabbits	intramuscular (<i>m. sacrospinalis</i>)	Cement degradation increased with Sr/(Sr+Ca) molar ratio during intramuscular implantation for 24 weeks, reaching approx. 50% in the 10% substituted group.	106
		drill hole (2.2 mm)	After 4-24 weeks degradation increased with Sr-content (up to 10%). Good integration of 10% SrCPC was found. Sr was located in the newly mineralised surrounding tissue.	
SrHA (pre-set)	3 month old Sprague-Dawley rats	drill hole (2.5x4 mm) metaphyseal	Enhanced endochondral ossification was found in the 10% Sr-CPC group after 2 weeks, whilst after 4-16 weeks post-operation progressive osteo-conduction was found in both groups.	107
n/a (α -TCP based)	10 week old Sprague-Dawley rats (♀) 2 months after OVX, OPen	drill hole (2 mm) metaphyseal	After 1, 3 and 6 months, SrCPC exhibited increased fragmentation. Faster osseointegration and increased new bone formation were found in the SrCPC group compared to Sr-free reference. Fragmentation promoted implant integration.	91
SrHA	10 week old Sprague-Dawley rats (♀), 12 weeks after OVX, D, OPen	metaphyseal, 4 mm wedge-shaped, bridged with osteosynthesis plate	After 6 weeks significant increase of new bone formation in SrCPC group against CPC and empty defect was found. Up-regulation of bone-specific markers bone-morphogenic protein-2, osteocalcin, osteoprotegerin and alkaline phosphatase; increased collagen formation. Sr ²⁺ were found in the newly formed bone tissue around the implant.	127
ZnSr-brushite	pig (♂, n=2)	drill hole (3.5x10 mm ³) trabecular	After 1 and 2 months highest new bone formation with the most pronounced organisation level was found in the SrZn-group compared to Sr-free ZnCPC and CDHA cement control (commercial). Less osteoclasts were found around SrZnCPC.	117

OVX: ovariectomized; **D:** animals received calcium and phosphate deficient diet; **OPen:** animals had confirmed pre-implantation osteopenic bone status.

4 Conclusions

A variety of approaches towards strontium-substituted calcium phosphate bone cements has been published in the last years. Most of them are based on the use of Sr-containing phases that are intermixed with the conventional precursor powder or substitute CaP phases therein, whilst others use the cement liquid to introduce Sr²⁺ into the cement. The resulting cements can be categorised in those that set into mono- or multiphasic matrices that are characterised by a homogenous Sr distribution or contain Sr rich clusters, respectively. In general, Sr substituted CPC are characterised by an enhanced degradability both under laboratory conditions and *in vivo*. Given the differences in the phase composition and porosity of the cements no general conclusion on the effects of Sr modification on the mechanical properties of the set cements can be drawn, but an increased strength has been found in many compositions setting into monophasic SrHA, whereas multi-phasic cements tend to have lower strength. The stimulatory effect of Sr²⁺ released from the cements has clearly been shown *in vitro*, although the use of various cell types that may have different susceptibilities to Sr²⁺ concentrations, varying experimental setups and cement characteristics (e.g. porosity) prohibit general conclusions on the optimal degree of substitution. There remains a need to study the influence of Sr modification on bone resorbing cells *in vitro*. However, evidence exists from a few *in vivo* studies that the potential of Sr²⁺ to stimulate bone formation can be used to locally enhance new bone formation without systemic side effects. Therefore, strontium modified calcium phosphate bone cements are promising materials that could help to improve clinical outcome in the regeneration of bone defects, in particular in case of those in the diseased, e.g. osteoporotic, bone.

Acknowledgements

This work was funded by the German Research Foundation (DFG) as part of the Collaborative Research Centre/Transregio 79 (SFB/TR 79).

5 References

- 1 K. A. Hing, *Math Phys Eng Sci*, 2004, **362**, 2821-2850.
- 2 J. H. Shepherd, D. V. Shepherd and S. M. Best, *J Mater Sci Mater Med*, 2012, **23**, 2335-2347.
- 3 S. V. Dorozhkin, *J Mater Sci*, 2007, **42**, 1061-1095.
- 4 L. L. Hench and J. M. Polak, *Science*, 2002, **295**, 1014-1017.
- 5 A. Ruys, *J Aust Ceram Soc*, 1993, **29**, 71-80.
- 6 I. R. Gibson, S. M. Best, and W. Bonfield, *J Biomed Mater Res*, 1999, **44**, 422-428.
- 7 Z. Huan and J. Chang, *J Mater Sci Mater Med*, 2009, **20**, 833-841.
- 8 G. Mestres, C. Le Van, and M.-P. Ginebra, *Acta Biomater*, 2012, **8**, 1169-1179.
- 9 A. Bigi, G. Falini, E. Foresti, A. Ripamonti, M. Gazzano, and N. Roveri, *J Inorg Biochem*, 1993, **49**, 69.
- 10 Z. Zyman, M. Tkachenko, M. Epple, M. Polyakov, and M. Naboka, *Mat.-wiss. u. Werkstofftech.*, 2006, **37**, 474-477.
- 11 K. J. Lilley, U. Gbureck, J. C. Knowles, D. F. Farrar, and J. E. Barralet, *J Mater Sci Mater Med*, 2005, **16**, 455-460.
- 12 P. Habibovic and J. E. Barralet, *Acta Biomater*, 2011, **7**, 3013-3026.
- 13 M.-P. Ginebra, C. Canal, M. Espanol, D. Pastorino and E. B. Montufar, *Adv Drug Deliv Rev*, 2012, **64**, 1090-1110.
- 14 P. J. Marie, *Curr Opin Pharmacol*, 2005, **5**, 633-636.
- 15 P. S. Nielsen, *Bone*, 2004, **35**, 583-588.
- 16 Toxicological profile for strontium (no authors given), Strontium CAS#: 7440-24-6, Department of Health And Human Services, *Public Health Service Agency for Toxic Substances and Disease Registry*, 2004.
- 17 O. R. Leeuwenkamp, W. J. van der Vijgh, B. C. Hüsken, P. Lips and J. C. Netelenbos, *Calcif Tissue Int*, 1990, **47**, 136-141.
- 18 E. Shorr and A. C. Carter, *Bull Hosp Joint Dis*, 1952, **13**, 59-66.
- 19 J. McCaslin and F. E. Janes, *Proc Staff Meetings Mayo Clin*, 1959, **34**, 329-334.
- 20 S. C. Skoryna, *Can Med Assoc J*, 1981, **125**, 703-712.
- 21 T. Morohashi, T. Sano, K. Harai and S. Yamada, *Jpn J Pharmacol*, 1995, **68**, 153-159.
- 22 J. Y. Reginster, E. Seeman, M. C. De Vernejoul, S. Adami, J. Compston, C. Phenekos, J. P. Devogelaer, M. D. Curiel, A. Sawicki, S. Goemaere, O. H. Sorensen, D. Felsenberg and P. J. Meunier, *J Clin Endocrinol Metab*, 2005, **90**, 2816-2822.
- 23 P. J. Meunier, C. Roux, S. Ortolani, M. Diaz-Curiel, J. Compston, P. Marquis, C. Cormier, G. Isaia, J. Badurski, J. D. Wark, J. Collette and J. Y. Reginster, *Osteoporos Int*, 2009, **20**, 1663-1673.
- 24 P. J. Marie, *Curr Opin Rheumatol*, 2006, **18**, S11-S15.
- 25 P. J. Marie, *Bone*, 2007, **40**, S5-S8.

- 26 E. Bonnelye, A. Chabadel, F. Saltel and P. Jurdic, *Bone*, 2008, **42**, 129–138.
- 27 J. Braux, F. Velard, C. Guillaume, S. Bouthors, E. Jallot, J.-M. Nedelec, D. Laurent-Maquin and P. Laquerrière, *Acta Biomater*, 2011, **7**, 2593–2603.
- 28 E. Canalis, M. Hott, P. Deloffre, Y. Tsouderos and P. J. Marie, *Bone*, 1996, **18**, 517–523.
- 29 S. C. Verberckmoes, M. E. De Broe and P. C. D'Haese, *Kidney Int*, 2003, **64**, 534–543.
- 30 N. Chattopadhyay, S. J. Quinn, O. Kifor, C. Ye and E. M. Brown, *Biochem Pharmacol*, 2007, **74**, 438–447.
- 31 P. J. Marie, *Bone*, 2010, **46**, 571–576.
- 32 F. Yang, D. Yang, J. Tu, Q. Zheng, L. Cai, and L. Wang, *Stem Cells*, 2011, **29**, 981–991.
- 33 S. Peng, X. S. Liu, S. Huang, Z. Li, H. Pan, W. Zhen, K. D. K. Luk, X. E. Guo and W. W. Lu, *Bone*, 2011, **49**, 1290–1298.
- 34 A. D. Bakker, B. Zandieh-Doulabi, and J. Klein-Nulend, *Bone*, 2013, **53**, 112–119.
- 35 S. Choudhary, P. Halbout, C. Alander, L. Raisz and C. Pilbeam, *J Bone Miner Res*, 2007, **22**, 1002–1010.
- 36 A. S. Hurtel-Lemaire, R. Mentaverri, A. Caudrillier, F. Cournarie, A. Wattel, S. Kamel, E. F. Terwilliger, E. M. Brown and M. Brazier, *J Biol Chem*, 2009, **284**, 575–584.
- 37 R. LeGeros, A. Chohayeb and A. Shulman, *J Dent Res*, 1982, **61**, 343.
- 38 W. Brown and L. Chow, *J Dent Res*, 1983, **62**, 672.
- 39 W. Brown and L. Chow, *US Patent RE33*, 1990, 221.
- 40 M. Bohner, *Injury*, 2000, **31**, 37–47, 2000.
- 41 F. C. Driessens, J. A. Planell, M. G. Boltong, I. Khairoun, and M. P. Ginebra, *Proc Inst Mech Eng H*, 1998, **212**, 427–435.
- 42 O. Bermúdez, M. G. Boltong, F. C. M. Driessens and J. A. Planell, *J Mater Sci Mater Med*, 1994, **5**, 160–163.
- 43 J. Lacout, E. Mejdoubi and M. Hamad, *J Mater Sci Mater Med*, 1996, **7**, 371–374.
- 44 F. C. M. Driessens, E. A. de Maeyer, E. Fernandez, M. G. Boltong, G. Berger, R. M. Verbeeck, M. P. Ginebra and J. A. Planell, *Bioceramics*, 1996, **9**, 231–234.
- 45 M. P. Ginebra, E. Fernández, E. A. de Maeyer, R. M. Verbeeck, M. G. Boltong, J. Ginebra, F. C. Driessens and J. A. Planell, *J Dent Res*, 1997, **76**, 905–912.
- 46 D. Knaack, M. E. Goad, M. Aiolova, C. Rey, A. Tofighi, P. Chakravarthy and D. D. Lee, *J Biomed Mater Res*, 1998, **43**, 399–409.
- 47 L. M. Grover, J. C. Knowles, G. J. P. Fleming and J. E. Barralet, *Biomaterials*, 2003, **24**, 4133–4141.
- 48 C. D. Friedman, P. D. Costantino, S. Takagi and L. C. Chow, *J Biomed Mater Res*, 1998, **43**, 428–432.
- 49 S. V. Dorozhkin, *Biomatter*, 2011, **1**, 121–164.
- 50 E. Fernández, F. J. Gil, M. P. Ginebra, F. C. Driessens, J. A. Planell and S. M. Best, *J Mater Sci Mater Med*, 1999, **10**, 169–176.
- 51 M. A. Aia, J. E. Mathers and R. W. Mooney, *J Chem Eng Data*, 1964, **9**, 335–338.

- 52 P. Patnaik, Handbook of Inorganic Chemicals. McGraw-Hill Handbooks, McGraw-Hill, 2002.
- 53 J. Dean and N. Lange, Lange's handbook of chemistry. Lange's Handbook of Chemistry, McGraw-Hill, 1992.
- 54 J. Christoffersen, M. R. Christoffersen, N. Kolthoff and O. Barenholdt, *Bone*, 1997, **20**, 47–54.
- 55 H. B. Pan, Z. Y. Li, W. M. Lam, J. C. Wong, B. W. Darvell, K. D. K. Luk and W. W. Lu, *Acta Biomater*, 2009, **5**, 1678–1685.
- 56 M. H. Alkhraisat, C. Rueda and E. López Cabarcos, *J Funct Biomater*, 2011, **2**, 31–38.
- 57 A. A. Mirtchi, J. Lemaître and N. Terao, *Biomaterials*, 1989, **10**, 475–480.
- 58 M. Bohner and U. Gbureck, *J Biomed Mater Res B Appl Biomater*, 2008, **84**, 375–385.
- 59 M. Bohner, J. Lemaître and T. A. Ring, *J Am Ceram Soc*, 1996, **79**, 1427–1434.
- 60 B. R. Constantz, B. M. Barr, I. C. Ison, M. T. Fulmer, J. Baker, L. McKinney, S. B. Goodman, S. Gunasekaren, D. C. Delaney, J. Ross and R. D. Poser, *J Biomed Mater Res*, 1998, **43**, 451–461.
- 61 D. Apelt, F. Theiss, A. O. El-Warrak, K. Zlinszky, R. Bettschart-Wolfisberger, M. Bohner, S. Matter, J. A. Auer and B. von Rechenberg, *Biomaterials*, 2004, **25**, 1439–1451.
- 62 A. Malsy and M. Bohner, *Eur Cell Mater*, 2005, **10**, 28.
- 63 Z. Xia, L. M. Grover, Y. Huang, I. E. Adamopoulos, U. Gbureck, J. T. Triffitt, R. M. Shelton and J. E. Barralet, *Biomaterials*, 2006, **27**, 4557–4565.
- 64 Y. W. Li, J. C. Y. Leong, W. W. Lu, K. D. K. Luk, K. M. C. Cheung, K. Y. Chiu and S. P. Chow, *J Biomed Mater Res*, 2000, **52**, 164–170.
- 65 C. Drouet, M.-T. Carayon, C. Combes, and C. Rey, *Mater Sci Eng C*, 2008, **28**, 1544–1550.
- 66 I. R. de Lima, G. G. Alves, C. A. Soriano, A. P. Campaneli, T. H. Gasparoto, E. S. Ramos, Jr, L. de Sena, A. M. Rossi and J. M. Granjeiro, *J Biomed Mater Res A*, 2011, **98**, 351–358.
- 67 E. Rokita, C. Hermes, H. F. Nolting and J. Ryczek, *J Cryst Growth*, 1993, **130**, 541–552.
- 68 A. Bigi, E. Boanini, C. Capuccini and M. Gazzano, *Inorg Chim Acta*, 2007, **360**, 1009–1016.
- 69 J. E. Huheey, E. A. Keiter, R. L. Keiter and R. Steudel, *Anorganische Chemie / Prinzipien von Struktur und Reaktivität*. de Gruyter, Berlin [u.a.], 3 ed., 2003.
- 70 E. Landi, A. Tampieri, G. Celotti, S. Sprio, M. Sandri and G. Logroscino, *Acta Biomater*, 2007, **3**, 961–969.
- 71 M. D. O'Donnell, Y. Fredholm, A. de Rouffignac and R. G. Hill, *Acta Biomater*, 2008, **4**, 1455–1464.
- 72 A. Bigi, E. Foresti, M. Gandolfi, M. Gazzano and N. Roveri, *J Inorg Biochem*, 1997, **66**, 259–265.
- 73 S. J. Saint-Jean, C. L. Camire, P. Nevsten, S. Hansen and M. P. Ginebra, *J Mater Sci Mater Med*, 2005, **16**, 993–1001.


- 74 M. H. Alkhraisat, C. Moseke, L. Blanco, J. E. Barralet, E. López Carbacos and U. Gbureck, *Biomaterials*, 2008, **29**, 4691–4697.
- 75 S. Panzavolta, P. Torricelli, L. Sturba, B. Bracci, R. Giardino and A. Bigi, *J Biomed Mater Res A*, 2008, **84**, 965–972.
- 76 U. Gbureck, J. E. Barralet, K. Spatz, L. M. Grover, and R. Thull, *Biomaterials*, 2004, **25**, 2187–2195.
- 77 K. S. TenHuisen and P. W. Brown, *J Biomed Mater Res*, 1997, **36**, 306–314.
- 78 M. Bohner, H. Tiainen, P. Michel, and N. Döbelin, *J Mater Sci Mater Med*, 2015, **26**, 63.
- 79 H.-B. Pan, Z.-Y. Li, T. Wang, W. M. Lam, C. T. Wong, B. W. Darvell, K. D. K. Luk, Y. Hu, and W. W. Lu, *Cryst Growth Des*, 2009, **9**, 3342–3345.
- 80 L. C. Chow, *Dent Mater J*, 2009, **28**, 1–10.
- 81 G.-M. Kuang, W. P. Yau, W. M. Lam, J. Wu, K. Y. Chiu, W. W. Lu and H. Pan, *J Biomed Mater Res B Appl Biomater*, 2012, **100**, 778–787.
- 82 M. Watanabe, M. Tanaka, M. Sakurai and M. Maeda, *J Eur Ceram Soc*, 2006, **26**, 549–552.
- 83 D. Guo, K. Xu, X. Zhao and Y. Han, *Biomaterials*, 2005, **26**, 4073–4083.
- 84 D. Guo, M. Mao, W. Qi, H. Li, P. Ni, G. Gao and K. Xu, *J Mater Sci Mater Med*, 2011, **22**, 2631–2640.
- 85 S. Tadier, R. Bareille, R. Siadous, O. Marsan, C. Charvillat, S. Cazalbou, J. Amédée, C. Rey and C. Combes, *J Biomed Mater Res B*, 2011, **100B**, 378–390.
- 86 M. Schumacher, A. Henß, M. Rohnke and M. Gelinsky, *Acta Biomater*, 2013, **9**, 7536–7544.
- 87 X. Wang, J. Ye and Y. Wang, *Acta Biomater*, 2007, **3**, 757–763.
- 88 G. Romieu, X. Garric, S. Munier, M. Vert and P. Boudeville, *Acta Biomater*, 2010, **6**, 3208–3215.
- 89 X. Wang and J. Ye, *J Mater Sci Mater Med*, 2008, **19**, 1183–1186.
- 90 T. Yu, J. Ye and Y. Wang, *Acta Biomater*, 2009, **5**, 2717–2727.
- 91 M. Baier, P. Staudt, R. Klein, U. Sommer, R. Wenz, I. Grafe, P. J. Meeder, P. P. Nawroth and C. Kasperk, *J Orthop Surg Res*, 2013, **8**, 16.
- 92 Y. Shen, J. Liu, K. Lin and W. Zhang, *Mater Lett*, 2012, **70**, 76–79.
- 93 E. Fujihara, M. Kon and K. Asaoka, *Key Eng Mater*, 2007, **330-332**, 795–798.
- 94 L. Leroux, M. Frèche and J. Lacout, *Key Eng Mater*, 2001, **192-195**, 235–238.
- 95 S. Pina, P. M. Torres, F. Goetz-Neunhoeffler, J. Neubauer and J. M. F. Ferreira, *Acta Biomater*, 2010, **6**, 928–935.
- 96 S. Pina, P. M. C. Torres and J. M. F. Ferreira, *J Mater Sci Mater Med*, 2010, **21**, 431–438.
- 97 E. Boanini, S. Panzavolta, K. Rubini, M. Gandolfi and A. Bigi, *Acta Biomater*, 2010, **6**, 936–942.
- 98 M. Schumacher, A. Lode, A. Helth and M. Gelinsky, *Acta Biomater*, 2013, **9**, 9547–9557.

- 99 S. Heinemann, S. Rössler, M. Lemm, M. Ruhnow, and B. Nies, *Acta Biomater*, 2013, **9**, 6199–6207.
- 100 M. Bohner, U. Gbureck, and J. Barralet, *Biomaterials*, 2005, **26**, 6423–6429.
- 101 S. C. Verberckmoes, G. J. Behets, L. Oste, A. R. Bervoets, L. V. Lamberts, M. Drakopoulos, A. Somogyi, P. Cool, W. Dorriné, M. E. De Broe and P. C. D'Haese, *Calcif Tissue Int*, 2004, **75**, 405–415.
- 102 A. Reinstorf, U. Hempel, F. Olgemöller, H. Domaschke, W. Schneiders, R. Mai, B. Stadlinger, A. Rösen-Wolff, S. Rammelt, M. Gelinsky and W. Pompe, *Materialwiss Werkstofftech*, 2006, **37**, 491–503.
- 103 J. Gustavsson, M. P. Ginebra, E. Engel and J. Planell, *Acta Biomater*, 2011, **7**, 4242–4252.
- 104 S. Maeno, Y. Niki, H. Matsumoto, H. Morioka, T. Yatabe, A. Funayama, Y. Toyama, T. Taguchi and J. Tanaka, *Biomaterials*, 2005, **26**, 4847–4855.
- 105 Y. K. Liu, Q. Z. Lu, R. Pei, H. J. Ji, G. S. Zhou, X. L. Zhao, R. K. Tang and M. Zhang, *Biomed Mater*, 2009, **4**, 025004.
- 106 D. Guo, K. Xu and Y. Han, *J Biomed Mater Res A*, 2008, **86**, 947–958.
- 107 G.-M. Kuang, W. P. Yau, J. Wu, K. W. K. Yeung, H. Pan, W. M. Lam, W. W. Lu and K. Y. Chiu, *J Biomed Mater Res A*, 2014, **00A**, 1552–4965.
- 108 D. R. Carter and W. C. Hayes, *J Bone Joint Surg Am*, 1977, **59**, 954–962.
- 109 E. Charriere, S. Terrazzone, C. Pittet, P. H. Mordasini, M. Dutoit, J. Lemaître and P. H. Zysset, *Biomaterials*, 2001, **22**, 2937–2945.
- 110 G. Cama, F. Barberis, R. Botter, P. Cirillo, M. Capurro, R. Quarto, S. Scaglione, E. Finocchio, V. Mussi and U. Valbusa, *Acta Biomater*, 2009, **5**, 2161–2168.
- 111 H. Andrianjatovo, F. Jose and J. Lemaître, *J Mater Sci Mater Med*, 1996, **7**, 34–39.
- 112 O. Bermúdez, M. Boltong, F. C. Driessens and J. Planell, *J Mater Sci Mater Med*, 1993, **4**, 389–393.
- 113 J. Engstrand, J. Jacob, H. Engqvist and C. Persson, in *The 23rd Interdisciplinary Research Conference on Injectable Osteoarticular Biomaterials and Bone Augmentation Procedures - GRIBOI: Proceedings*, 2013.
- 114 A. López, M. Montazerolghaem, H. Engqvist, M. K. Ott and C. Persson, *J Biomed Mater Res B Appl Biomater*, 2014, **102**, 250–259.
- 115 V. Medri, M. Mazzocchi and A. Bellosi, *J Mater Sci Mater Med*, 2011, **22**, 229–236.
- 116 M. Rohnke, A. Henß, J. Kokesch-Himmelreich, M. Schumacher, S. Ray, V. Alt, M. Gelinsky and J. Janek, *Anal Bioanal Chem*, 2013, **405**, 8769–8780.
- 117 S. Pina, S. I. Vieira, P. Rego, P. M. C. Torres, O. A. B. da Cruz e Silva, E. F. da Cruz e Silva and J. M. F. Ferreira, *Eur Cell Mater*, 2010, **20**, 162–177.
- 118 L. Yang, S. Perez-Amodio, F. Y. F. Barrère-de Groot, V. Everts, C. A. van Blitterswijk and P. Habibovic, *Biomaterials*, 2010, **31**, 2976–2989.
- 119 Y. L. Ma, Q. Q. Zeng, L. L. Porras, A. Harvey, T. L. Moore, T. L. Shelbourn, G. P. Dalsky, T. J. Wronski, J. I. Aguirre, H. U. Bryant and M. Sato, *Endocrinology*, 2011, **152**, 1767–1778.

- 120 G. X. Ni, K. Y. Chiu, W. W. Lu, Y. Wang, Y. G. Zhang, L. B. Hao, Z. Y. Li, W. M. Lam, S. B. Lu and K. D. K. Luk, *Biomaterials*, 2006, **27**, 4348–4355.
- 121 W. W. Lu, K. M. Cheung, Y. W. Li, K. D. Luk, A. D. Holmes, Q. A. Zhu and J. C. Leong, *Spine (Phila Pa 1976)*, 2001, **26**, 2684–2690.
- 122 Z. Li, N. Yuan, R. W. M. Lam, Z. Cui, X. Yang and W. W. Lu, *Mater Sci Eng C Mater Biol Appl*, 2013, **33**, 5100–5104.
- 123 C. T. Wong, W. W. Lu, W. K. Chan, K. M. C. Cheung, K. D. K. Luk, D. S. Lu, A. B. M. Rabie, L. F. Deng and J. C. Y. Leong, *J Biomed Mater Res A*, 2004, **68**, 513–521.
- 124 C. T. Wong, Q. Z. Chen, W. W. Lu, J. C. Y. Leong, W. K. Chan, K. M. C. Cheung and K. D. K. Luk, *J Biomed Mater Res A*, 2004, **70**, 428–435.
- 125 G.-M. Kuang, W. P. Yau, W. W. Lu and K. Y. Chiu, *Am J Sports Med*, 2014, **42**, 2996–3002.
- 126 V. Alt, U. Thormann, S. Ray, D. Zahner, L. Dürselen, K. Lips, T. El Khassawna, C. Heiss, A. Riedrich, G. Schlewitz, A. Ignatius, M. Kampschulte, H. von Dewitz, S. Heinemann, R. Schnettler and A. Langheinrich, *Acta Biomater*, 2013, **9**, 7035–7042.
- 127 U. Thormann, S. Ray, U. Sommer, T. ElKhassawna, T. Rehling, M. Hundgeburth, A. Henß, M. Rohnke, J. Janek, K. S. Lips, C. Heiss, G. Schlewitz, G. Szalay, M. Schumacher, M. Gelinsky, R. Schnettler and V. Alt, *Biomaterials*, 2013, **34**, 8589–8598.

TOC entry:

Strontium modified calcium phosphate cements can target local bone turnover by stimulating osteoblast proliferation and differentiation (1) as well as bone mineralisation (2), reducing osteoclastogenesis (3) and resorption activity, increase osteoclasts apoptosis (4) and affect osteoblast/osteoclast paracrine signalling (5).



29x21mm (600 x 600 DPI)